Long-term outcomes of gemcitabine and cisplatin in patients with recurrent or metastatic esophageal squamous cell carcinoma: A phase II trial

Chinese Medical Journal

Volumn 124, Issue 23, 2011, Pages 4012-4017

  Huang, Jing ^a   Fan, Qing Xia ^b   Chen, Li ^c   Liu, Ai Na ^a   Cai, Rui Gang ^a   Hao, Xue Zhi ^a   Wang, Jin Wan ^a   Sun, Yan ^a  

^a CANCER HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Chemotherapy; Cisplatin; Esophageal cancer; Gemcitabine

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LONG TERM CARE; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84862951928     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.23.031     Document Type: Article

References (18)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Sun Y. Medical treatment. In: Huang GJ, Wu YK, eds. Carcinoma of the esophagus and gastric cardia. Heidelberg: Springer-Verlag; 1984: 369-390.
3. Engstrom P, Lavin P, Klaassen DJ. Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep 1983; 67: 713-715.
4. Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, Hahn RG. Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 1980; 46: 2149-2153.
5. Ajani JA. Contributions of chemotherpy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 1994; 21: 474-482.
6. Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the oesophagus. CancerJ 2000; 6: 316-323.
7. Huang J, Cai RG, Mong PJ, Zhang MJ, Cui CX, Yang L, et al. Phase II study of paclitaxel and cisplatin in advanced squamous cell carcinoma of esophagus. Chin J Oncology (Chin) 2004; 26: 753-755.
8. Kaye SB. Gemcitabine: current status of phase I and phase II trials. J Clin Oncol 1994; 12: 1527-1531.
9. Kroep JR, Pinedo HM, Giaccone G, Van Bochove A, Peters GJ, Van Groeningen CJ. Phase II study of cisplatin preceding gemcitabine in patients with advanced esophageal cancer. Ann Oncol 2004; 15: 230-235.
10. Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, et al. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs 2004; 22: 91-97.
11. Millar J, Scullin P, Morrison A, McClory B, Wall L, Cameron D, et al. Phase II study of gemcitabine and cisplatin in locally advanced/metastatic esophageal cancer. Br J Cancer 2005; 14; 93: 1112-1116.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
13. Simon R. Optimal two stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
14. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
15. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17: 3270-3275.
16. Kim JY, Do YR, Park KU, Kim MK, Lee KH, Bae SH, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol 2010; 66: 31-36.
17. Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K, Takahashi T. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol 2010; 66: 1159-1165.
18. Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, et al. Prognostic factors for survival in patients with advanced esophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 2003; 89: 2045-2050.